Drugmaker AbbVie (ABBV -2.67%) stole the spotlight last week following its maiden voyage on the NYSE, but it's biotech Gilead (GILD 2.87%) -- AbbVie's chief rival in the hepatitis-C space -- that's taking a bow today.
Gilead is presenting at the J.P. Morgan Global Healthcare Conference and offered a preview showing that its experimental hepatitis-C drugs are marching steadily through phase 2 and 3 trials. In this video, health care analyst Max Macaluso runs down this news and explains what led to Gilead's modest 1.5% pop today.
